PRTKのニュース
Paratek Pharmaceuticals: Patience Is Wearing Thin 2022/08/24 17:29:18 Seeking Alpha
Paratek Pharmaceuticals is advancing its flagship product nicely, but shareholders have not been rewarded yet. What lies ahead for PRTK stock? Read more to know.
Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) Fall -34.42% In Six Months, Here’s What We Should Expect Now 2022/08/06 19:00:00 Marketing Sentinel
During the last session, Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)’s traded shares were 0.41 million, with the beta value of the company hitting 1.54. At the end of the trading day, the stock’s price was $2.61, reflecting an intraday gain of 1.16% or $0.03. The 52-week high for the PRTK share is $6.26, that puts it down … Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) Fall -34.42% In Six Months, Here’s What We Should Expect Now Read More »
Paratek Pharmaceuticals (PRTK) Q2 2022 Earnings Call Transcript 2022/08/04 05:30:40 The Motley Fool
PRTK earnings call for the period ending June 30, 2022.
Paratek Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation (NASDAQ:PRTK) 2022/08/04 04:36:52 Seeking Alpha
The following slide deck was published by Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q2 2022 Results - Earnings Call Transcript 2022/08/04 02:27:08 Seeking Alpha
Paratek Pharmaceuticals, Inc. (NASDAQ:NASDAQ:PRTK) Q2 2022 Earnings Conference Call August 03, 2022, 16:30 ET Company Participants Sarah Higgins - VP, Controller and Interim Principal…
Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Insider Sells 4,479 Shares of Stock 2021/12/18 13:02:42 Transcript Daily
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) insider Randall B. Brenner sold 4,479 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, December 13th. The stock was sold at an average price of $4.42, for a total transaction of $19,797.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which []
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel Sells $21,551.92 in Stock 2021/12/18 13:02:42 Dakota Financial News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 4,876 shares of the companys stock in a transaction dated Monday, December 13th. The shares were sold at an average price of $4.42, for a total transaction of $21,551.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []
William M. Haskel Sells 17,178 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock 2021/12/17 13:42:46 Transcript Daily
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 17,178 shares of Paratek Pharmaceuticals stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $4.27, for a total value of $73,350.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []
Randall B. Brenner Sells 15,780 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock 2021/12/17 13:42:45 Dakota Financial News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) insider Randall B. Brenner sold 15,780 shares of the firms stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $4.27, for a total value of $67,380.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. []
Head-To-Head Comparison: Paratek Pharmaceuticals (NASDAQ:PRTK) and Tricida (NASDAQ:TCDA) 2021/11/27 13:48:42 Dakota Financial News
Paratek Pharmaceuticals (NASDAQ:PRTK) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk and Volatility Paratek Pharmaceuticals has a beta of 1.5, suggesting that its stock price is []
Head-To-Head Comparison: Paratek Pharmaceuticals (NASDAQ:PRTK) and Tricida (NASDAQ:TCDA) 2021/11/27 13:48:42 Dakota Financial News
Paratek Pharmaceuticals (NASDAQ:PRTK) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk and Volatility Paratek Pharmaceuticals has a beta of 1.5, suggesting that its stock price is []
Northern Trust Corp Sells 5,228 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) 2021/11/23 09:18:42 Transcript Daily
Northern Trust Corp lowered its holdings in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 1.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 481,062 shares of the specialty pharmaceutical companys stock after selling 5,228 shares during the period. Northern Trust Corp owned approximately 0.99% of []
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Expected to Post Quarterly Sales of $33.52 Million 2021/11/15 21:12:43 Transcript Daily
Equities research analysts expect Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report $33.52 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Paratek Pharmaceuticals earnings, with the lowest sales estimate coming in at $31.64 million and the highest estimate coming in at $35.39 million. Paratek Pharmaceuticals reported sales of $16.02 million []
Paratek Pharmaceuticals (NASDAQ:PRTK) Given New $27.00 Price Target at HC Wainwright 2021/11/10 10:34:44 Transcript Daily
Paratek Pharmaceuticals (NASDAQ:PRTK) had its price target lowered by HC Wainwright from $28.00 to $27.00 in a research note published on Tuesday, Analyst Ratings Network reports. The brokerage currently has a buy rating on the specialty pharmaceutical companys stock. Separately, Zacks Investment Research raised shares of Paratek Pharmaceuticals from a sell rating to a hold []